Abstract
Abstract
Rationale
Electronic nicotine delivery systems (ENDS) are used by smokers seeking to reduce combustible cigarette (CC) use, but the role of nicotine replacement vs. behavioral and sensory factors is still poorly understood. We hypothesized that providing nicotine from ENDS in addition to nicotine skin patches would promote smoking reduction relative to non-nicotine control ENDS.
Objectives
To assess the effects on smoking behavior of using nicotine vs. placebo ENDS in smokers using nicotine vs. placebo patches.
Methods
Ninety-four daily smokers were enrolled in a study that randomly assigned them to receive ENDS with nicotine vs. without nicotine and skin patches with vs. without nicotine. Smoking reduction and cessation were assessed over an 8-week period by self-report and by expired air carbon monoxide (CO) measurements. The primary outcome was defined as reduction in expired air CO.
Results
The use of nicotine in ENDS led to significant reductions in smoking (ENDS nicotine vs. placebo difference in CO change = −9.2 ppm; 90% CI (−1.5 ppm, −16.9 ppm)) and was highly correlated with reductions in self-reported cigarettes per day (r=0.6). The effect of nicotine in nicotine patches was not statistically significant (patch nicotine vs. placebo difference in CO change = −0.1 ppm; 90% CI (−7.8 ppm, 7.6 ppm)).
Conclusions
The presence of nicotine in ENDS was associated with a large reduction in smoking. Additional studies will be needed to determine whether there may be additive effects of nicotine ENDS and nicotine patches on smoking abstinence.
Funder
National Institute on Drug Abuse
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Adriaens K, Belmans E, Van Gucht D, Baeyens F (2021) Electronic cigarettes in standard smoking cessation treatment by tobacco counselors in Flanders: e-cigarette users show similar if not higher quit rates as those using commonly recommended smoking cessation aids. Harm Reduct J 18(1):28. https://doi.org/10.1186/s12954-021-00475-7
2. Benowitz NL, Zevin S, Jacob P (1998) 3rd Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine. J Pharmacol Exp Ther 287(3):958–962
3. Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A (1999) Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. BMJ 318(7179):285–288. https://doi.org/10.1136/bmj.318.7179.285 Erratum in: BMJ 1999 Mar 20;318(7186):764. PMID: 9924052; PMCID: PMC27708
4. Callahan-Lyon P, Sipes G (2018) Tobacco product or medical product? Presentation at the Society for Research on Nicotine & Tobacco’s Annual Meeting, held February 21, 2018 in Baltimore, Maryland. https://www.fda.gov/media/118946/download
5. Carter BD, Abnet CC, Feskanich D, Freedman ND, Hartge P, Lewis CE, Ockene JK, Prentice RL, Speizer FE, Thun MJ, Jacobs EJ (2015) Smoking and mortality—beyond established causes. NEJM 372(7):631–640. https://doi.org/10.1056/NEJMsa1407211
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献